Johnson & Johnson (J&J), of New Brunswick, N.J., soared in its second quarter, with pharmaceuticals leading the way. While pharma took top billing, devices beat what had been forecast, with worldwide sales of $6.49 billion. That figure came above the $6.43 billion consensus, as Cowen's Joshua Jennings noted.